Date:
August 5, 2026
Content:
The U.S. Food and Drug Administration (FDA) has released a regulatory update regarding Fresenius Kabi USA LLC, specifically concerning its manufacturing operations in Melrose Park, Illinois.
This recent publication references oversight activities and inspection data for the Melrose Park facility, identified under FDA record number 1450022. The update follows an assessment period originally dated in February 2026, as part of the agency’s ongoing commitment to monitoring pharmaceutical manufacturing standards and facility compliance.
Fresenius Kabi is a major provider of essential medicines and technologies for infusion, transfusion, and clinical nutrition. Regular updates from the FDA ensure that these facilities meet the rigorous safety and quality requirements necessary for distributing healthcare products in the United States.
Source: U.S. Food and Drug Administration
Link:
http://www.fda.gov/about-fda/fresenius-kabi-usa-llc
Keywords:
FDA, Fresenius Kabi USA, Melrose Park IL, Pharmaceutical Manufacturing, Regulatory Compliance